Patents by Inventor Mark D. Bednarski

Mark D. Bednarski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
    Patent number: 11925617
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: March 12, 2024
    Assignees: NORTHROP GRUMMAN SYSTEMS, CORPORATION and EPICENTRX, INC.
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF
    Publication number: 20220016077
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: February 26, 2021
    Publication date: January 20, 2022
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF
    Publication number: 20200046682
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: March 14, 2019
    Publication date: February 13, 2020
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
    Patent number: 10149832
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: December 11, 2018
    Assignees: EpicentRx, Inc., Orbital ATK, Inc.
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF
    Publication number: 20180085346
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: August 4, 2017
    Publication date: March 29, 2018
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF
    Publication number: 20160199346
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: December 10, 2015
    Publication date: July 14, 2016
    Inventors: MARK D. BEDNARSKI, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
    Patent number: 9226915
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: January 5, 2016
    Assignees: EPICENTRX, INC., ORBITAL ATK, INC.
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • O-nitro compounds and pharmaceutical compositions including same
    Patent number: 9133150
    Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: September 15, 2015
    Assignee: ORBITAL ATK, INC.
    Inventors: Mark D. Bednarski, Susan Knox, Louis F. Cannizzo, Kirstin F. Warner, Robert B. Wardle, Stephen P. Velarde, Shoucheng Ning
  • CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF
    Publication number: 20150246020
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: December 29, 2014
    Publication date: September 3, 2015
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
    Patent number: 8927527
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: October 19, 2012
    Date of Patent: January 6, 2015
    Assignees: EpicentRx, Inc., Alliant Techsystems Inc.
    Inventors: Mark D. Bednarski, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • O-NITRO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS INCLUDING SAME
    Publication number: 20130309324
    Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: July 26, 2013
    Publication date: November 21, 2013
    Applicants: RadioRx, Inc., c/o Interwest Venture Partners, Alliant Techsystems Inc.
    Inventors: Mark D. Bednarski, Susan Knox, Louis F. Cannizzo, Kristin F. Warner, Robert B. Wardle, Stephen P. Velarde, Shoucheng Ning
  • Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
    Patent number: 8299053
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: March 4, 2009
    Date of Patent: October 30, 2012
    Assignees: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Mark D. Bednarski, Lynn M. Oehler, legal representative, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • PHARMACEUTICAL COMPOSITIONS OF O-NITRO COMPOUNDS
    Publication number: 20120237615
    Abstract: The present invention provides O-nitro compounds, pharmaceutical compositions of O-nitro compounds and methods of using O-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: May 30, 2012
    Publication date: September 20, 2012
    Applicants: RADIORX, INC., C/O INTERWEST VENTURE PARTNERS, ALLIANT TECHSYSTEMS INC.
    Inventors: Mark D. Bednarski, Lynn M. Oehler, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Targeted cross-linked nanoparticles and their use in vivo gene delivery
    Patent number: 8163305
    Abstract: The in vivo delivery of nucleic acids is targeted by delivery of the nucleic acid in a complex with cross-linked nanoparticles; where the nanoparticles comprise cross-linked neutral amphipathic molecules, cationic amphipathic molecules and targeting amphipathic molecules. Optionally the cationic and targeting amphipathic molecules are also cross-linked. A targeting moiety present on the targeting amphipathic molecule provides for selective delivery of the complex to a predetermined target site, e.g. blood vessels, endothelial cells, tumor cells, liver cells, and the like.
    Type: Grant
    Filed: August 20, 2008
    Date of Patent: April 24, 2012
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark D. Bednarski, Samira Guccione, King Chuen Li
  • X-NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF
    Publication number: 20090291935
    Abstract: The present invention provides X-nitro compound, pharmaceutical compositions of X-nitro compounds and methods of using X-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: April 23, 2009
    Publication date: November 26, 2009
    Applicant: RadioRx, Inc.
    Inventors: Mark D. BEDNARSKI, Lynn M. Oehler, Andrew C. Haaland, Susan J. Knox
  • CYCLIC NITRO COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF AND USES THEREOF
    Publication number: 20090163466
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: March 4, 2009
    Publication date: June 25, 2009
    Applicants: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Mark D. Bednarski, Lynn M. Oehler, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning
  • Use of targeted cross-linked nanoparticles for in vivo gene delivery
    Patent number: 7514098
    Abstract: The in vivo delivery of nucleic acids is targeted by delivery of the nucleic acid in a complex with cross-linked nanoparticles; where the nanoparticles comprise cross-linked neutral amphipathic molecules, cationic amphipathic molecules and targeting amphipathic molecules. Optionally the cationic and targeting amphipathic molecules are also cross-linked. A targeting moiety present on the targeting amphipathic molecule provides for selective delivery of the complex to a predetermined target site, e.g. blood vessels, endothelial cells, tumor cells, liver cells, and the like.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: April 7, 2009
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Mark D. Bednarski, Samira Guccione, King Chuen Li
  • Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
    Patent number: 7507842
    Abstract: The present invention provides cyclic nitro compound, pharmaceutical compositions of cyclic nitro compounds and methods of using cyclic nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Grant
    Filed: August 11, 2006
    Date of Patent: March 24, 2009
    Assignees: RadioRx, Inc., Alliant Techsystems Inc.
    Inventors: Lynn M. Oehler, legal representative, Susan Knox, Louis Cannizzo, Kirstin Warner, Robert Wardle, Stephen Velarde, Shoucheng Ning, Mark D. Bednarski
  • USE OF TARGETED CROSS-LINKED NANOPARTICLES FOR IN VIVO GENE DELIVERY
    Publication number: 20090048201
    Abstract: The in vivo delivery of nucleic acids is targeted by delivery of the nucleic acid in a complex with cross-linked nanoparticles; where the nanoparticles comprise cross-linked neutral amphipathic molecules, cationic amphipathic molecules and targeting amphipathic molecules. Optionally the cationic and targeting amphipathic molecules are also cross-linked. A targeting moiety present on the targeting amphipathic molecule provides for selective delivery of the complex to a predetermined target site, e.g. blood vessels, endothelial cells, tumor cells, liver cells, and the like.
    Type: Application
    Filed: August 20, 2008
    Publication date: February 19, 2009
    Inventors: Mark D. Bednarski, Samira Guccione, King Chuen Li
  • X-nitro compounds, pharmaceutical compositions thereof and uses thereof
    Publication number: 20040167212
    Abstract: The present invention provides X-nitro compound, pharmaceutical compositions of X-nitro compounds and methods of using X-nitro compounds and/or pharmaceutical compositions thereof to treat or prevent diseases or disorders characterized by abnormal cell proliferation, such as cancer, inflammation, cardiovascular disease and autoimmune disease.
    Type: Application
    Filed: October 7, 2003
    Publication date: August 26, 2004
    Inventors: Mark D. Bednarski, Andrew C. Haaland, Susan J. Knox